CancerVax announces promotions
Cancer research company CancerVax has promoted Dr Martin Mattingly to executive vice president and chief operating officer; Hazel Aker, JD, to senior vice president, regulatory operations and legal affairs; and Dr Carol Gallagher, to vice president, sales, marketing and product planning.
Cancer research company CancerVax has promoted Dr Martin Mattingly to executive vice president and chief operating officer; Hazel Aker, JD, to senior vice president, regulatory operations and legal affairs; and Dr Carol Gallagher, to vice president, sales, marketing and product planning.
Dr John Petricciani will continue to serve as senior vice president, medical and regulatory affairs, focusing on the company's strategic regulatory direction and interactions with regulatory authorities.
'These promotions reflect the significant contributions Martin, Hazel and Carol have made to CancerVax,' said David Hale, CancerVax's president and chief executive officer. 'Their leadership and management skills have been critical in helping CancerVax build a multi-product biotechnology company focused on the development of innovative products for the treatment of cancer.'